Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Survodutide

Survodutide (BI 456906)

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 12 September 2026

Survodutide is a real, investigational glucagon/GLP-1 dual receptor agonist from Boehringer Ingelheim and Zealand Pharma, and it's the furthest along in Phase 3 of any dual/triple-agonist obesity peptide currently covered on this site. A completed, published Phase 2 obesity trial and positive Phase 3 topline results in both obesity (SYNCHRONIZE-1, April 2026) and MASLD/fatty liver disease (SYNCHRONIZE-MASLD, June 2026) are real and specific — but they are still topline, company-announced results rather than full peer-reviewed publications as of this review, and no regulatory filing has been approved anywhere yet.

On this page
  1. What it is, and the mechanism
  2. The completed Phase 2 evidence
  3. The 2026 Phase 3 topline results
  4. What's still unresolved

In brief

Should you care? Yes if you've read this site's retatrutide or cagrilintide pages — survodutide is the same general "next-generation GLP-1-family" story, but with real completed Phase 2 data already published and positive Phase 3 topline results already announced in two separate indications.

The short version

  • A glucagon/GLP-1 dual receptor agonist — a distinct mechanism from tirzepatide (GIP/GLP-1) or retatrutide (GIP/GLP-1/glucagon).
  • A completed, published Phase 2 obesity trial found roughly 18.6% weight loss at 46 weeks in the highest dose group, versus placebo.
  • Positive Phase 3 topline results announced in 2026 in both obesity (16.6% weight loss at 76 weeks vs. 3.2% placebo, p<0.0001) and MASLD — real, specific, but not yet full peer-reviewed publications.

What it is, and the mechanism

Survodutide (BI 456906) is a synthetic peptide co-developed by Boehringer Ingelheim and Zealand Pharma that activates both the glucagon receptor and the GLP-1 receptor. This combination is mechanistically distinct from tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/glucagon triple agonist), both covered elsewhere on this site: adding glucagon-receptor agonism is intended to increase energy expenditure on top of GLP-1's appetite-suppressing effect, and is a specific rationale for survodutide's parallel development in metabolic liver disease (MASLD/MASH), where glucagon-receptor activity may directly reduce liver fat.

The completed Phase 2 evidence

A randomized, double-blind, placebo-controlled Phase 2 dose-finding trial (le Roux et al., Lancet Diabetes Endocrinol 2024, PMID 38330987) tested survodutide at four doses (0.6mg to 4.8mg weekly) against placebo in adults with overweight or obesity without type 2 diabetes, over 46 weeks. Patients on the highest (4.8mg) dose lost approximately 18.6% of body weight — a real, published, peer-reviewed, placebo-controlled result. A separate Phase 2 trial in MASH with fibrosis (Sanyal et al., N Engl J Med 2024, PMID 38847460) also reported positive liver-disease endpoints.

The 2026 Phase 3 topline results

Boehringer Ingelheim announced positive topline results from the Phase 3 SYNCHRONIZE-1 obesity trial on April 28, 2026: survodutide met its co-primary weight-loss endpoints and a key secondary (waist circumference), producing average weight loss of up to 16.6% at 76 weeks (efficacy estimand) versus 3.2% with placebo (p<0.0001). In June 2026, the companies also announced positive results from the Phase 3 SYNCHRONIZE-MASLD trial, reporting liver-fat normalization in roughly 6 of 10 treated participants with MASLD and obesity/overweight at 48 weeks, alongside reported reductions in visceral fat (~34%) and liver fat (~63%) in a pre-specified analysis. Two further Phase 3 trials, in more advanced MASH/fibrosis populations, are ongoing.

A genuinely stronger starting position than most peptides in this drug class get on this site. Unlike several entries here that rest only on animal data or a single small trial, survodutide already has two separate published, peer-reviewed, randomized Phase 2 trials in two different indications before even reaching its Phase 3 program.

What's still unresolved

The 2026 Phase 3 figures are company press-release topline results rather than full peer-reviewed manuscripts as of this review — real and specific, but not yet independently scrutinized in the way the completed Phase 2 papers have been. Survodutide is not approved anywhere, no regulatory filing appears to have been submitted as of this review, and longer-term safety data (particularly any glucagon-receptor-specific safety signal, and anything analogous to the thyroid C-cell tumor signal seen in rodent studies for other GLP-1-family drugs) should be checked directly in the full trial publications once they appear.

References

  1. le Roux CW, Steen O, Lucas KJ, et al., "Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial," Lancet Diabetes Endocrinol 2024, PMID 38330987.
  2. Sanyal AJ et al., survodutide Phase 2 trial in MASH with fibrosis, N Engl J Med 2024, PMID 38847460.
  3. Boehringer Ingelheim press release, Phase 3 SYNCHRONIZE-1 topline results, 28 April 2026 (company-reported, not yet peer-reviewed).
  4. Boehringer Ingelheim / Zealand Pharma press release, Phase 3 SYNCHRONIZE-MASLD topline results, June 2026 (company-reported, not yet peer-reviewed).